IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes

Affiliations

Review

T A Wynn et al. Res Immunol. 1995 Sep-Oct.

. 1995 Sep-Oct;146(7-8):582-90.

doi: 10.1016/0923-2494(96)83035-5.

¹ Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.

No abstract available

Similar articles

Interleukins and colon cancer.
Caro-Patón Gómez A. Caro-Patón Gómez A. Rev Esp Enferm Dig. 2005 Sep;97(9):613-8. doi: 10.4321/s1130-01082005000900001. Rev Esp Enferm Dig. 2005. PMID: 16266233 English, Spanish. No abstract available.
Role of recombinent interleukin-12 as an adjuvant on vaccine-induced immunity in murine Schistosoma mansoni infection.
Abdel-Aaty HE, Ramadan NI, Mahmoud MS, Abdel-Aziz SS, Khalil HM, El-Badawy NM, Khalil HH. Abdel-Aaty HE, et al. J Egypt Soc Parasitol. 1999;29(1):1-11. J Egypt Soc Parasitol. 1999. PMID: 12561877
Development of an antipathology vaccine for schistosomiasis.
Wynn TA. Wynn TA. Ann N Y Acad Sci. 1996 Oct 25;797:191-5. doi: 10.1111/j.1749-6632.1996.tb52960.x. Ann N Y Acad Sci. 1996. PMID: 8993362 Review.
Vaccination against Schistosoma mansoni infection using 74 kDa Schistosoma protein antigen.
Attallah AM, Attia H, Ismail H, Yones E, El-Nashar EM, Abd El-Kader K, Tabll A, Saad A, Sultan A. Attallah AM, et al. Vaccine. 1999 Jul 16;17(22):2786-91. doi: 10.1016/s0264-410x(99)00090-0. Vaccine. 1999. PMID: 10438048
Role of IL12 as an anti-tumour agent: current status and future directions.
Brunda MJ. Brunda MJ. Res Immunol. 1995 Sep-Oct;146(7-8):622-28. doi: 10.1016/0923-2494(96)83040-9. Res Immunol. 1995. PMID: 8839170 Review. No abstract available.

Interleukin-12 in infectious diseases.
Romani L, Puccetti P, Bistoni F. Romani L, et al. Clin Microbiol Rev. 1997 Oct;10(4):611-36. doi: 10.1128/CMR.10.4.611. Clin Microbiol Rev. 1997. PMID: 9336665 Free PMC article. Review.